Phase III clinical trials in patients with mild to moderate Alzheimer's disease , more than half reduced the progression of the disease. Therapy included the removal of β-amyloid from the blood, not from the brain. Levels β-amyloid are dynamic, and there is a balance between its amount in the brain and in the blood. 3r314. Past trials 3r374. showed that reducing the level of β-amyloid in the blood can reduce its presence in the brain, which is the result of a new equilibrium.
 
The test seems to be an important confirmation of r3r319. amyloid hypothesis
Alzheimer's disease, just at the time of its intense criticism. A history of unsuccessful attempts to reduce β-amyloid levels led to a variety of competing initiatives and increased attention to r3r321. tau aggregation 3r3r74. as the main cause of pathology in the later stages of the disease. I also see in the test some signs in favor of the concept of 3r3323. disorders of filtration of the CSF in the brain 3r3r74. . In it are the ways by which CSF leaves the brain, atrophies with age, and the rate of metabolic waste collection decreases.
 
blind 3r374. ,
placebo controlled r3r374. , a parallel group clinical trial in which patients with mild to moderate Alzheimer's disease from 41 centers in Europe and the United States participated. The purpose of the test was to evaluate the efficacy and safety of a short-term replacement 3r3341. plasma r3r374. and then long-term
plasmapheresis with injections human albumin 3r3r74. in combination with intravenous infusion
immunoglobulin 3r374. in patients with mild to moderate Alzheimer's disease.
 
 
AMBAR is based on the hypothesis that most β-amyloid accumulated in the brain of Alzheimer's patients is bound to albumin and circulates in plasma. Removing this plasma can lead to the migration of β-amyloid from the brain to the plasma, which reduces the effect of the disease on the cognitive functions of the patient. In addition, albumin can be an integrated approach to the treatment of the disease because of its binding ability, antioxidant, immunomodulating and anti-inflammatory properties.
 
 
The AMBAR trial included 496 patients with mild and moderate Alzheimer's disease, randomized in three treatment groups, and one 3r-357. the placebo group . The participants were 55-85 years old, and the effectiveness of the treatment was measured by changes in cognition and in terms of daily life. An independent research organization (CRO) controlled the clinical trial and the steps of collecting and analyzing information. Randomized and 3r3359 were used in the trial. double blind control
, and this meant that patients, doctors, and evaluators did not know whether the patients used the treatment or placebo.
 
 
AMBAR analyzes have shown positive, very relevant results in patients with moderate Alzheimer's disease. Doctors found a reduction in progression of 50-75% in the cognitive scale of Alzheimer's disease (3-336365. ADAS-Cog 3r3-374.) And 42-70% in the scale of daily life (3r367. ADCS-ADL
) In patients receiving treatment. Including all patients receiving plasma replacement, the difference was 66% for the ADAS-Cog scale and 52% for the ADCS-ADL scale.
 
 
3r373. www.grifols.com/en/view-news/-/new/grifols-ambar-results-demonstrate-a-significant-reduction-in-the-progression-of-moderate-alzheimers-disease
! function (e) {function t (t, n) {if (! (n in e)) {for (var r, a = e.document, i = a.scripts, o = i.length; o-- ;) if (-1! == i[o].src.indexOf (t)) {r = i[o]; break} if (! r) {r = a.createElement ("script"), r.type = "text /jаvascript", r.async =! ? r.defer =! ? r.src = t, r.charset = "UTF-8"; var d = function () {var e = a.getElementsByTagName ("script")[0]; e.parentNode.insertBefore (r, e)}; "[object Opera]" == e.opera? a.addEventListener? a.addEventListener ("DOMContentLoaded", d,! 1): e.attachEvent ("onload", d ): d ()}}} t ("//mediator.mail.ru/script/2820404/"""_mediator") () (); 3r380.